Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by stanleyon Apr 19, 2013 7:41am

128 Views

Post# 21273824

RE: BRD AGM - Delta Barrington HFX NS May 29 2013

Kewl2:

[S] Clarification of the time of the AGM.

"Brigus's annual general meeting will be held at the Delta Barrington Hotel in Halifax, N.S., on Wednesday, May 29, 2013, at 11 a.m. Atlantic Time (noon Eastern Time). "

Cheers

Stanley

Bullboard Posts

StockTalk | Cannabis Report: New CEO, new dispensaries, new strains